221 related articles for article (PubMed ID: 9816257)
1. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD
Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257
[TBL] [Abstract][Full Text] [Related]
2. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
[TBL] [Abstract][Full Text] [Related]
3. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
[TBL] [Abstract][Full Text] [Related]
4. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Bigner DD; Brown MT; Friedman AH; Coleman RE; Akabani G; Friedman HS; Thorstad WL; McLendon RE; Bigner SH; Zhao XG; Pegram CN; Wikstrand CJ; Herndon JE; Vick NA; Paleologos N; Cokgor I; Provenzale JM; Zalutsky MR
J Clin Oncol; 1998 Jun; 16(6):2202-12. PubMed ID: 9626222
[TBL] [Abstract][Full Text] [Related]
5. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Reardon DA; Quinn JA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Dowell JM; Rich JN; Vredenburgh JJ; Desjardins A; Sampson JH; Gururangan S; Wong TZ; Badruddoja MA; Zhao XG; Bigner DD; Zalutsky MR
J Nucl Med; 2006 Jun; 47(6):912-8. PubMed ID: 16741299
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
Akabani G; Reist CJ; Cokgor I; Friedman AH; Friedman HS; Coleman RE; Zhao XG; Bigner DD; Zalutsky MR
J Nucl Med; 1999 Apr; 40(4):631-8. PubMed ID: 10210222
[TBL] [Abstract][Full Text] [Related]
7. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
10. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Cokgor I; Akabani G; Kuan CT; Friedman HS; Friedman AH; Coleman RE; McLendon RE; Bigner SH; Zhao XG; Garcia-Turner AM; Pegram CN; Wikstrand CJ; Shafman TD; Herndon JE; Provenzale JM; Zalutsky MR; Bigner DD
J Clin Oncol; 2000 Nov; 18(22):3862-72. PubMed ID: 11078500
[TBL] [Abstract][Full Text] [Related]
12. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.
Riva P; Franceschi G; Frattarelli M; Lazzari S; Riva N; Giuliani G; Casi M; Sarti G; Guiducci G; Giorgetti G; Gentile R; Santimaria M; Jermann E; Maeke HR
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3275s-3280s. PubMed ID: 10541375
[TBL] [Abstract][Full Text] [Related]
13. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
Schuster JM; Garg PK; Bigner DD; Zalutsky MR
Cancer Res; 1991 Aug; 51(16):4164-9. PubMed ID: 1714341
[TBL] [Abstract][Full Text] [Related]
14. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
Bigner DD; Brown M; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Bigner SH; Zhao XG; Wikstrand CJ; Pegram CN
J Neurooncol; 1995; 24(1):109-22. PubMed ID: 8523067
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.
Lee YS; Bullard DE; Zalutsky MR; Coleman RE; Wikstrand CJ; Friedman HS; Colapinto EV; Bigner DD
Cancer Res; 1988 Feb; 48(3):559-66. PubMed ID: 2446747
[TBL] [Abstract][Full Text] [Related]
16. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
[TBL] [Abstract][Full Text] [Related]
17. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
Kraeber-Bodéré F; Bardet S; Hoefnagel CA; Vieira MR; Vuillez JP; Murat A; Ferreira TC; Bardiès M; Ferrer L; Resche I; Gautherot E; Rouvier E; Barbet J; Chatal JF
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3190s-3198s. PubMed ID: 10541363
[TBL] [Abstract][Full Text] [Related]
19. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
20. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
